Skip to main content

Eva Polverino

Institutions of which they are part

Main researcher
Pneumology
Vall Hebron Institut de Recerca

Eva Polverino

Institutions of which they are part

Main researcher
Pneumology
Vall Hebron Institut de Recerca

Projects

Contribución de la disfunción de CFTR al desarrollo y agresividad del cáncer de páncreas. Estimulación del crecimiento tumoral y metástasis por células estrelladas carentes de CFTR.

IP: Contribución de la disfunción de CFTR al desarrollo y agresividad del cáncer de páncreas. Estimulación del crecimiento tumoral y
Collaborators: Laura Campderros Traver, Eva Polverino
Funding agency: Instituto de Salud Carlos III
Funding: 147620
Reference: PI22/00887
Duration: 01/01/2023 - 31/12/2025

Grup de Recerca en Pneumologia

IP: Jaume Ferrer Sancho
Collaborators: Sergi Martí Beltran, Marta Vicenta Arjona Perís, Christian Eduardo Romero Mesones, Maria Angeles Jiménez Fuentes, Mª Jose Jurado Luque, Marc Miravitlles Fernández, Ana Villar Gomez, Antonio Álvarez Fernandez, Victor Monforte Torres, Odile Romero Santo-Tomas, Miriam Barrecheguren Fernández, David Clofent Alarcón, Carles Bravo Masgoret, Mario Culebras Amigo, Fco. Javier Muñoz Gall, Gabriel Sampol Rubio, Maria Antonia Ramon Belmonte, Mercedes Pallero Castillo, Mª Jesús Cruz Carmona, Cristina Berastegui Garcia, Almudena Felipe Montiel, Eva Maria Revilla Lopez, Gerard Orriols Torras, Julia Sampol Sirvent, Meritxell Boada Perez, David Espejo Castellanos, Manuel López Meseguer, David Soler Segovia, Susana Gómez Olles, Berta Saez Gimenez, Iñigo Ojanguren Arranz, Eva Polverino, Letizia Traversi
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 0.01
Reference: 2021 SGR 00788
Duration: 01/01/2022 - 30/06/2025

ECRAID-Base (European Clinical Research Alliance for Infectious Diseases) H2020-SC1-2020-Single-Stage-RTD Grant agreement ID: 965313

IP: Eva Polverino
Collaborators: Monica Kruger
Funding agency: EUROPEAN COMMISSION
Funding: 21875
Reference: ECRAID-H2020-SC1-BHC-35-2020
Duration: 01/03/2021 - 28/02/2026

COVID-19, PERFIL INMUNOLÓGICO DE RIESGO

IP: COVID-19, PERFIL INMUNOLÓGICO DE RIESGO
Collaborators: Manuel Hernández González, Mónica Martínez Gallo, Moisés Labrador Horrillo, Gema Codina Grau, Albert Blanco Grau, Andres Antón Pagarolas, Antonio Álvarez Fernandez, Nuria Fernández Hidalgo, Roser Ferrer Costa, Esteve Ribera Pascuet, Juan Carlos Ruiz Rodriguez, Jaume Ferrer Sancho, Anna Suy Franch, Pere Soler Palacín, Albert Selva O'Callaghan, Tomàs Pumarola Suñé, Isabel Ruiz Camps, Daniel Alvarez De la Sierra, Andrea Martín Nalda, Eva Polverino, Romina Dieli Crimi, Romina Dieli Crimi
Funding agency: Instituto de Salud Carlos III
Funding: 229000
Reference: COV20/00416
Duration: 08/05/2020 - 08/11/2021

Related news

Dr. Miravitlles’ career was recognized during the 57th edition of the SEPAR National Congress held in Valencia.

Vall d'Hebron participated in the study in which more than half of the patients who received treatment with bacteriophages experienced significant improvements

La recerca és fonamental per contrarestar els efectes de la pol·lució, que segons l’AEMPS, va ser la causa de més de 300.000 morts prematures a la UE el 2020.

Related professionals

Anna Duarri Piqué

Anna Duarri Piqué

Main researcher
Ophtalmology
Read more
Maria Belén Viñado Perez

Maria Belén Viñado Perez

Read more
Laura González Mora

Laura González Mora

Administrative Assistant
Communication Unit
Communication Directorate
Read more
Montse Bach Oller

Montse Bach Oller

Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.